- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.02. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.02.2026 | 741 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.02.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.02.2026ISIN NameAU0000234676 ENRG... ► Artikel lesen | |
| 02.02. | Aquaporin A/S - Removal from trading on Nasdaq Copenhagen | 229 | GlobeNewswire | Aquaporin A/S (the company) will be removed from trading on Nasdaq Copenhagen due to the company having been declared bankrupt.
Trading in the company's shares has been suspended since 30 January... ► Artikel lesen | |
| 02.02. | Aquaporin A/S: Bankruptcy order issued for Aquaporin A/S | 174 | GlobeNewswire (Europe) | Company announcement
No. 05/2026Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694Kongens Lyngby, Denmark, February 2, 2026 - The Bankruptcy Court... ► Artikel lesen | |
| 30.01. | XFRA 00B: AUSSETZUNG/SUSPENSION | 155 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAQUAPORIN A/S DK... ► Artikel lesen | |
| AQUAPORIN Aktie jetzt für 0€ handeln | |||||
| 30.01. | Aquaporin A/S: Aquaporin announces withdrawal of its offering and resolves to initiate insolvency proceedings | 589 | PR Newswire | Company announcement No. 04/2026 Inside informationAquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694KONGENS LYNGBY, Denmark, Jan. 30, 2026... ► Artikel lesen | |
| 30.01. | Suspension of Trading in Aquaporin A/S at XCSE | 157 | GlobeNewswire | 2026-01-30T07:41:57Z
Suspension
At Trading Venue XCSE
Due to Technical Or
Administrative
Ongoing: True
Comments: We refer to company announcement No. 04
2026 disclosed by Aquaporin on January 30... ► Artikel lesen | |
| 26.01. | Aquaporin A/S: Aquaporin further postpones final results of rights issue due to current investor dialogues and uncertainty of completion | 156 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT... ► Artikel lesen | |
| 23.01. | Aquaporin A/S - Observation status | 147 | GlobeNewswire | Nasdaq Copenhagen has today given the below observation status:
ISIN NAME:
DK0061555109 AQUAPORIN
The company is given observation status because the company... ► Artikel lesen | |
| 23.01. | Aquaporin A/S: Aquaporin postpones final results of rights issue due to uncertainty of completion and its ability to remain a going concern | 181 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT... ► Artikel lesen | |
| 02.01. | Aquaporin A/S: Last day of trading in shares with pre-emptive rights in connection with rights issue | 397 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| 02.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.01.2026 | 355 | Xetra Newsboard | Das Instrument 00B DK0061555109 AQUAPORIN A/S DK 1 EQUITY wird cum Kapitalmassnahme gehandelt am 02.01.2026 und ex Kapitalmassnahme am 05.01.2026 The instrument 00B DK0061555109 AQUAPORIN A/S DK 1 EQUITY... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S - rights issue, admission to trading and official listing of subscription rights | 274 | GlobeNewswire | Subscription rights in Aquaporin A/S will be admitted to trading and official listing on Nasdaq Copenhagen as of 5 January 2026. As of the same date, ISIN DK0061555109 (AQP) will be traded excl.... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin initiates rights issue | 354 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin updates on strategic review and sets mid-and long-term financial targets | 402 | PR Newswire | Company announcementNo. 21/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 19.12.25 | AQUAPORIN A/S: Aquaporin updates on strategic review and sets mid- and long-term financial targets | 2 | Cision News | ||
| 01.12.25 | Business transacted at the extraordinary general meeting of Aquaporin A/S | 322 | PR Newswire | Company announcementNo. 20/2025Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany reg. no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 1, 2025 /PRNewswire/ -- Aquaporin A/S... ► Artikel lesen | |
| 01.12.25 | Aquaporin A/S: Business transacted at the extraordinary general meeting of Aquaporin A/S | 169 | GlobeNewswire (Europe) | Company announcement
No. 20/2025
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company reg. no.: DK28315694
Kongens Lyngby, Denmark, December 1, 2025 - Aquaporin A/S ("Aquaporin"... ► Artikel lesen | |
| 13.11.25 | Aquaporin A/S: Aquaporin Q3 2025 Trading Statement | 244 | PR Newswire | Company announcement
No. 19/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11.25 | Aquaporin A/S: Notice to convene an extraordinary general meeting | 435 | PR Newswire | Company announcement
No. 18/2025
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 07.11.25 | Aquaporin A/S: Update on strategic review and intention to strengthen financial position | 387 | PR Newswire | Company announcement
No. 17/2025Inside information
Aquaporin A/S
Nymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | +1,38 % | Qiagen: Analysten sehen Wettbewerbssorgen als übertrieben | Nach Gesprächen mit dem Qiagen-Management auf Analysten-Konferenzen in den USA stufen Analysten die Aktie des Diagnostikspezialisten weiterhin positiv ein. Jefferies beließ es bei einer Kaufempfehlung... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 62,98 | -2,63 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights | Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS... ► Artikel lesen | |
| ARCELLX | 113,80 | -0,05 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| EVOTEC | 5,880 | +0,38 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| BIONTECH | 93,10 | -0,21 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,100 | -2,26 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 14,750 | -79,74 % | Novartis Pharma AG: Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy | Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar... ► Artikel lesen | |
| CARDIO DIAGNOSTICS | 6,490 | +24,33 % | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 336,75 | -1,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,820 | -3,48 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| RELAY THERAPEUTICS | 10,250 | +12,02 % | Relay Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ADMA BIOLOGICS | 15,580 | +2,70 % | ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance | ||
| EDGEWISE THERAPEUTICS | 30,450 | +2,77 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,870 | -1,55 % | Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval | ||
| PRIME MEDICINE | 4,630 | +5,71 % | Prime Medicine, Inc.: Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates | -- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as... ► Artikel lesen |
Das Unternehmen AQUAPORIN A/S kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,053 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AQUAPORIN A/S finden Sie auf Wallstreet Online.